Abstract

Hypophosphatasia (HPP) is a rare multisystem inherited metabolic disorder caused by mutations in ALPL gene that encodes tissue nonspecific alkaline phosphatase responsible for bone mineralization. HPP is characterized by impaired bone mineralization, skeletal abnormalities, and systemic manifestations which result in significant morbidity and mortality. Clinical presentations of HPP vary greatly. Early (perinatal and infantile) HPP is characterized by the most severe symptoms, i.e., respiratory and neurological disorders are of crucial importance being the leading causes of death. Progressive skeletal impairment, rickets-like deformities, reduced mobility, and severe disability are typical of childhood-onset HPP. The biochemical hallmark of HPP is low alkaline phosphatase (ALP) activity. HPP diagnosis is verified by clinical symptoms in combination with persistently low ALP activity (adjusted for age and sex). Molecular genetic test to identify ALPL gene mutation is performed as needed. Three case reports addresses authors’ experience with the diagnosis and treatment for HPP.Keywords: hypophosphatasia, case series, alkaline phosphatase, impaired bone mineralization, asfotase alfa.For citation: Boykov S.A., Chernyak I.Yu., Shatokhina N.S. et al. Hypophosphatasia in children. Three faces of one disease. Russian Journal of Woman and Child Health. 2020;3(2):136–141. DOI: 10.32364/2618-8430-2020-3-2-136-141.

Highlights

  • Гипофосфатазия (ГФФ) — это мультисистемное прогрессирующее наследственное метаболическое заболевание, зачастую приводящее к угрожающим жизни состояниям и инвалидизации пациентов [1]

  • a rare multisystem inherited metabolic disorder caused by mutations in ALPL gene that encodes tissue nonspecific alkaline phosphatase

  • HPP is characterized by impaired bone mineralization

Read more

Summary

Introduction

Гипофосфатазия (ГФФ) — это мультисистемное прогрессирующее наследственное метаболическое заболевание, зачастую приводящее к угрожающим жизни состояниям и инвалидизации пациентов [1]. Для ГФФ характерны дефекты формирования и развития опорно-двигательного аппарата — укорочения, всевозможные деформации конечностей, грудной клетки, черепа. С 03.11.18 по жизненным показаниям инициирована фермент-заместительная терапия лекарственным препаратом асфотаза альфа в дозе 2 мг на 1 кг массы тела 3 р./нед.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call